ArticleScientific reports2025
A radiomics model predicts progression from mild cognitive impairment to alzheimer's disease using structural MRI.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Olfactory radiomics signatures link pTau217 to cognitive impairment in probable Alzheimer's disease: a multi-cohort machine learning study.Alzheimer's research & therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The aim of this study is to build and validate a model based on structural magnetic resonance imaging (sMRI) to predict the progression of mild cognitive impairment (MCI) to Alzheimer's disease (AD). A total of 343 patients with MCI were selected from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database as study subjects. Among them, 154 patients progressed to AD during the 48-month follow-up. All subjects were randomly divided into a training set (n = 240) and a validation set (n = 103) in a 7:3 ratio according to enrollment time. The baseline T1-weighted (T1W) structural MR images of each patient were automatically segmented into whole-brain three-dimensional (3D) white and gray matter images based on the training set data. In addition, radiomics signatures were extracted from each structural image. Baseline neuropsychological scores were combined with the radiomics signatures to construct a prediction model using machine learning. The diagnostic accuracy and reliability of the model were evaluated using the receiver operating characteristic (ROC) curve analysis in both the training and validation sets. Stepwise logistic regression analysis showed that clinical dementia rating (CDR), Alzheimer's Disease Assessment Scale (ADAS-cog) and radiomics markers were independent predictors of progression from MCI to AD. ROC curve showed that the AUC values of CDR, ADAS-cog and radiomics markers in the training set and validation set were 0.895 and 0.882, respectively. The sensitivity was 0.933 and 0.977, and the specificity was 0.669 and 0.661, respectively. DeLong test showed that the diagnostic efficacy of the comprehensive model was significantly different from that of the independent predictors (P = 0.023). The integrated model, based on structural analysis of magnetic resonance images, can accurately identify and predict individuals with MCI at high risk of progressing to AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.